In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings

Ageing Research Reviews

Volumn 36, Issue , 2017, Pages 50-63

  Hall, Benjamin ^a   Mak, Elijah ^a   Cervenka, Simon ^a,b   Aigbirhio, Franklin I ^c   Rowe, James B ^d,e,f   O'Brien, John T ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MEDICAL RESEARCH COUNCIL   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cognitive impairment; Dementia; MRI; Neurodegeneration; PET; Tau; Tauopathies

Indexed keywords

FDDNP F 18; FLORTAUCIPIR F 18; GENENTECH TAU PROBE 1 F 18; MK 6240 F 18; PBB 3 C 11; PBB 3 C 11 DERIVATIVE; RADIOLIGAND; RO 6958948 F 18; TAU PROTEIN; THK COMPOUND; TRACER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FLUORINE; FLUORINE-18;

AGING; ALZHEIMER DISEASE; AUTOPSY; BRAIN ATROPHY; BRAIN METABOLISM; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; HUMAN; IN VIVO STUDY; MICROTUBULE; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC POTENTIAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN PHOSPHORYLATION; REVIEW; RNA SPLICING; TAUOPATHY; WHITE MATTER; AMYLOID PLAQUE; ANIMAL; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PROCEDURES; TEMPORAL LOBE;

ALZHEIMER DISEASE; ANIMALS; BIOMARKERS; COGNITIVE DYSFUNCTION; DEMENTIA; FLUORINE RADIOISOTOPES; HUMANS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; TAU PROTEINS; TAUOPATHIES; TEMPORAL LOBE;

EID: 85015800559     PISSN: 15681637     EISSN: 18729649     Source Type: Journal    
DOI: 10.1016/j.arr.2017.03.002     Document Type: Review

References (134)

1. Agarwal, R., CSF tau and amyloid β42 levels in Alzheimer's disease—a meta-analysis. Adv. Alzheimer's Dis. 1 (2012), 30–44, 10.4236/aad.2012.13005.
2. Baker, S.L., Lockhart, S.N., Price, J.C., He, M., Huesman, R.H., Schonhaut, D., Faria, J., Rabinovici, G., Jagust, W.J., Reference tissue-based kinetic evaluation of 18F-AV-1451 in aging and dementia. J. Nucl. Med. 5279 (2016), 1–30, 10.2967/jnumed.116.175273.
3. Ballard, C., Ziabreva, I., Perry, R., Larsen, J.P., O'Brien, J., McKeith, I., Perry, E., Aarsland, D., Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67 (2006), 1931–1934, 10.1212/01.wnl.0000249130.63615.cc.
4. Barrio, J.R., Kepe, V., Satyamurthy, N., Huang, S.C., Small, G., Amyloid and tau imaging: neuronal losses and function in mild cognitive impairment. J. Nutr. Health Aging 12 (2008), 61S–65S.
5. Bevan Jones, W.R., Cope, T.E., Passamonti, L., Fryer, T.D., Hong, Y.T., Aigbirhio, F., Kril, J.J., Forrest, S.L., Allinson, K., Coles, J.P., Simon Jones, P., Spillantini, M.G., Hodges, J.R., O'Brien, J.T., Rowe, J.B., [8F]AV-1451 PET in behavioral variant frontotemporal dementia due to MAPT mutation. Ann. Clin. Transl. Neurol. 3 (2016), 940–947, 10.1002/acn3.366.
6. Bevan-Jones, W.R., Surendranathan, A., Passamonti, L., Vázquez Rodríguez, P., Arnold, R., Mak, E., Su, L., Coles, J.P., Fryer, T.D., Hong, Y.T., Williams, G., Aigbirhio, F., Rowe, J.B., O'Brien, J.T., Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. BMJ Open, 7, 2017, e013187, 10.1136/bmjopen-2016-013187.
7. Bhaskar, K., Konerth, M., Kokiko-Cochran, O.N., Cardona, A., Ransohoff, R.M., Lamb, B.T., Regulation of tau pathology by the microglial fractalkine receptor. Neuron 68 (2010), 19–31, 10.1016/j.neuron.2010.08.023.
8. Bloom, G.S., Amyloid-β and tau: the trigger and the bullet in Alzheimer's disease pathogenesis. JAMA Neurol., 71, 2014, 505, 10.1001/jamaneurol.2013.5847.
9. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82 (1991), 239–259.
10. Braak, H., Jellinger, K., Braak, E., Bohl, J., Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathol. 84 (1992), 478–483.
11. Brier, M.R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N.J., Holtzman, D.M., Fagan, A.M., Morris, J.C., Benzinger, T.L., Ances, B.M., Tau and A-beta imaging CSF measures, and cognition in Alzheimer's disease. Sci. Transl. Med. 8 (2016), 1–10, 10.1126/scitranslmed.aaf2362.
12. Burton, E.J., Barber, R., Mukaetova-Ladinska, E.B., Robson, J., Perry, R.H., Jaros, E., Kalaria, R.N., O'Brien, J.T., Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 132 (2009), 195–203, 10.1093/brain/awn298.
13. Ceravolo, R., Borghetti, D., Kiferle, L., Tognoni, G., Giorgetti, A., Neglia, D., Sassi, N., Frosini, D., Rossi, C., Petrozzi, L., Siciliano, G., Murri, L., CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease. Brain Res. Bull. 76 (2008), 80–84, 10.1016/j.brainresbull.2008.01.010.
14. Chetelat, G., La Joie, R., Villain, N., Perrotin, A., De La Sayette, V., Eustache, F., Vandenberghe, R., Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. NeuroImage Clin. 2 (2013), 356–365, 10.1016/j.nicl.2013.02.006.
15. Chhatwal, J.P., Schultz, A.P., Marshall, G.A., Boot, B., Gomez-Isla, T., Dumurgier, J., LaPoint, M., Scherzer, C., Roe, A.D., Hyman, B.T., Sperling, R.A., Johnson, K.A., Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 87 (2016), 920–926, 10.1212/WNL.;1;0000000000003050.
16. Chien, D.T., Bahri, S., Szardenings, A.K., Walsh, J.C., Mu, F., Su, M.Y., Shankle, W.R., Elizarov, A., Kolb, H.C., Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807. J. Alzheimer's Dis. 34 (2013), 457–468, 10.3233/JAD-122059.
17. Chiotis, K., Saint-Aubert, L., Savitcheva, I., Jelic, V., Andersen, P., Jonasson, M., Eriksson, J., Lubberink, M., Almkvist, O., Wall, A., Antoni, G., Nordberg, A., Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. Eur. J. Nucl. Med. Mol. Imaging 43 (2016), 1686–1699, 10.1007/s00259-016-3363-z.
18. Cho, H., Choi, J.Y., Hwang, M.S., Kim, Y.J., Lee, H.M., Lee, H.S., Lee, J.H., Ryu, Y.H., Lee, M.S., Lyoo, C.H., In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann. Neurol. 80 (2016), 247–258, 10.1002/ana.24711.
19. Cho, H., Choi, J.Y., Hwang, M.S., Lee, J.H., Kim, Y.J., Lee, H.M., Lyoo, C.H., Ryu, Y.H., Lee, M.S., Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 87 (2016), 375–383, 10.1212/WNL.;1;0000000000002892.
20. Cho, H., Choi, J.Y., Hwang, M.S., Lee, S.H., Ryu, Y.H., Lee, M.S., Lyoo, C.H., Subcortical 18-F-AV-1451 binding patterns in progressive supranuclear palsy. Mov. Disord. 0 (2016), 1–7, 10.1002/mds.26844.
21. Colloby, S.J., Firbank, M.J., Vasudev, A., Parry, S.W., Thomas, A.J., O'Brien, J.T., Cortical thickness and VBM-DARTEL in late-life depression. J. Affect. Disord. 133 (2011), 158–164, 10.1016/j.jad.2011.04.010.
22. Colloby, S.J., Firbank, M.J., He, J., Thomas, A.J., Vasudev, A., Parry, S.W., O'Brien, J.T., Regional cerebral blood flow in late-life depression: arterial spin labelling magnetic resonance study. Br. J. Psychiatry 200 (2012), 150–155, 10.1192/bjp.bp.111.092387.
23. Colom-Cadena, M., Gelpi, E., Charif, S., Belbin, O., Blesa, R., Marti, M.J., Clarimon, J., Lleo, A., Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 72 (2013), 1203–1212, 10.1097/NEN.;1;0000000000000018.
24. Crary, J.F., Trojanowski, J.Q., Schneider, J.A., Abisambra, J.F., Abner, E.L., Alafuzoff, I., Arnold, S.E., Attems, J., Beach, T.G., Bigio, E.H., Cairns, N.J., Dickson, D.W., Gearing, M., Grinberg, L.T., Hof, P.R., Hyman, B.T., Jellinger, K., Jicha, G.A., Kovacs, G.G., Knopman, D.S., Kofler, J., Kukull, W.A., Mackenzie, I.R., Masliah, E., McKee, A., Montine, T.J., Murray, M.E., Neltner, J.H., Santa-Maria, I., Seeley, W.W., Serrano-Pozo, A., Shelanski, M.L., Stein, T., Takao, M., Thal, D.R., Toledo, J.B., Troncoso, J.C., Vonsattel, J.P., White, C.L., Wisniewski, T., Woltjer, R.L., Yamada, M., Nelson, P.T., Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128 (2014), 755–766, 10.1007/s00401-014-1349-0.
25. Devous, M.D., Joshi, A.D., Navitsky, M.A., Dickson, J., Pontecorvo, M.A., Siderowf, A., Mintun, M.A., Test-retest data for the tau PET imaging agenet of 18F-AV-1451. Alzheimer's Dement., 10(4 Supplement), 2014, P901, 10.1016/j.jalz.2014.07.085.
26. Dickson, D.W., Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J. Neurol., 1999, II6–II15.
27. Fan, Z., Aman, Y., Ahmed, I., Chetelat, G., Landeau, B., Ray Chaudhuri, K., Brooks, D.J., Edison, P., Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimers Dement., 2014, 1–14, 10.1016/j.jalz.2014.06.016.
28. Firbank, M.J., Blamire, A.M., Teodorczuk, A., Teper, E., Burton, E.J., Mitra, D., O'Brien, J.T., High resolution imaging of the medial temporal lobe in Alzheimer's disease and dementia with Lewy bodies. J. Alzheimers Dis. 21 (2010), 1129–1140, 10.3233/JAD-2010-100138.
29. Firbank, M.J., Lloyd, J., O'Brien, J.T., The relationship between hallucinations and FDG-PET in dementia with Lewy bodies. Brain Imaging Behav. 10 (2016), 636–639, 10.1007/s11682-015-9434-0.
30. Fodero-Tavoletti, M.T., Okamura, N., Furumoto, S., Mulligan, R.S., Connor, A.R., McLean, C.A., Cao, D., Rigopoulos, A., Cartwright, G.A., O'Keefe, G., Gong, S., Adlard, P.A., Barnham, K.J., Rowe, C.C., Masters, C.L., Kudo, Y., Cappai, R., Yanai, K., Villemagne, V.L., 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134 (2011), 1089–1100, 10.1093/brain/awr038.
31. Fodero-Tavoletti, M.T., Furumoto, S., Taylor, L., McLean, C.A., Mulligan, R.S., Birchall, I., Harada, R., Masters, C.L., Yanai, K., Kudo, Y., Rowe, C.C., Okamura, N., Villemagne, V.L., Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res. Ther., 6, 2014, 11, 10.1186/alzrt240.
32. Frisoni, G.B., Fox, N.C., Jack, C.R., Scheltens, P., Thompson, P.M., The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6 (2010), 67–77, 10.1038/nrneurol.2009.215.
33. Gómez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., Parisi, J.E., Hyman, B.T., Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41 (1997), 17–24, 10.1002/ana.410410106.
34. Giannakopoulos, P., Herrmann, F.R., Bussière, T., Bouras, C., Kövari, E., Perl, D.P., Morrison, J.H., Gold, G., Hof, P.R., Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60 (2003), 1495–1500.
35. Gomperts, S.N., Locascio, J.J., Makaretz, S.J., Schultz, A., Caso, C., Vasdev, N., Sperling, R., Growdon, J.H., Dickerson, B.C., Johnson, K., Tau positron emission tomographic imaging in the lewy body diseases. JAMA Neurol. 72 (2016), 1–8, 10.1001/jamaneurol.2016.3338.
36. Greve, D.N., Svarer, C., Fisher, P.M., Feng, L., Hansen, A.E., Baare, W., Rosen, B., Fischl, B., Knudsen, G.M., Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data. Neuroimage 92 (2014), 225–236, 10.1016/j.neuroimage.2013.12.021.
37. Hahn, A., Schain, M., Erlandsson, M., Sjolin, P., James, G.M., Strandberg, O.T., Hagerstrom, D., Lanzenberger, R., Jogi, J., Olsson, T.G., Smith, R., Hansson, O., Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology. J. Nucl. Med.(October), 2016, 10.2967/jnumed.116.174508 Epub.
38. Hammes, J., Bischof, G.N., Giehl, K., Faber, J., Drzezga, A., Klockgether, T., van Eimeren, T., Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov. Disord. 0 (2016), 1–2, 10.1002/mds.26727.
39. Han, S.D., Gruhl, J., Beckett, L., Dodge, H.H., Stricker, N.H., Farias, S., Mungas, D., Alzheimer's Disease Neuroimaging Initiative, the A.D.N, Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. Brain Imaging Behav. 6 (2012), 610–620, 10.1007/s11682-012-9177-0.
40. Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., Ishikawa, Y., Matsuda, R., Inami, A., Yoshikawa, T., Tago, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 42 (2015), 1052–1061, 10.1007/s00259-015-3035-4.
41. Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., Ishikawa, Y., Matsuda, R., Inami, A., Yoshikawa, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer's disease. J. Nucl. Med. 57 (2015), 1–43, 10.2967/jnumed.115.164848.
42. Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., Miyake, M., Ishikawa, Y., Matsuda, R., Inami, A., Yoshikawa, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Arai, H., Kudo, Y., 18F-THK5351: a novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer's disease. J. Nucl. Med. 57 (2015), 1–43, 10.2967/jnumed.115.164848.
43. Harada, R., Okamura, N., Furumoto, S., Tago, T., Yanai, K., Arai, H., Kudo, Y., Characteristics of tau and its ligands in PET imaging. Biomolecules, 6, 2016, 7, 10.3390/biom6010007.
44. Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356, 10.1126/science.1072994.
45. Hashimoto, H., Kawamura, K., Igarashi, N., Takei, M., Fujishiro, T., Aihara, Y., Shiomi, S., Muto, M., Ito, T., Furutsuka, K., Yamasaki, T., Yui, J., Xie, L., Ono, M., Hatori, A., Nemoto, K., Suhara, T., Higuchi, M., Zhang, M.-R., Radiosynthesis, photoisomerization biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J. Nucl. Med. 55 (2014), 1532–1539, 10.2967/jnumed.114.139550.
46. Heneka, M.T., Carson, M.J., Khoury, J., El Landreth, G.E., Brosseron, F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., Herrup, K., Frautschy, S.A., Finsen, B., Brown, G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G.C., Town, T., Morgan, D., Shinohara, M.L., Perry, V.H., Holmes, C., Bazan, N.G., Brooks, D.J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D.T., Kummer, M.P., Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14 (2015), 388–405, 10.1016/S1474-4422(15)70016-5.
47. Hostetler, E.D., Walji, A.M., Zeng, Z., Miller, P., Bennacef, I., Salinas, C., Connolly, B., Gantert, L., Haley, H., Holahan, M., Purcell, M., Riffel, K., Lohith, T.G., Coleman, P., Soriano, A., Ogawa, A., Xu, S., Zhang, X., Joshi, E., Della Rocca, J., Hesk, D., Schenk, D.J., Evelhoch, J.L., Preclinical characterization of 18F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J. Nucl. Med. 57 (2016), 1599–1606, 10.2967/jnumed.115.171678.
48. Ikonomovic, M.D., Abrahamson, E.E., Price, J.C., Mathis, C.A., Klunk, W.E., [F-18]AV-1451 PET retention in choroid plexus: more than “off-target” binding. Ann. Neurol. 8 (2016), 2–3, 10.1002/ana.24706.
49. Innis, R.B., Cunningham, V.J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R.N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., Iida, H., Ito, H., Kimura, Y., Koeppe, R.A., Knudsen, G.M., Knuuti, J., Lammertsma, A.A., Laruelle, M., Logan, J., Maguire, R.P., Mintun, M.A., Morris, E.D., Parsey, R., Price, J.C., Slifstein, M., Sossi, V., Suhara, T., Votaw, J.R., Wong, D.F., Carson, R.E., Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J. Cereb. Blood Flow Metab. 27 (2007), 1533–1539, 10.1038/sj.jcbfm.9600493.
50. Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Kudo, Y., Arai, H., Longitudinal assessment of tau pathology in patients with Alzheimer's disease using [18F]THK-5117 positron emission tomography. PLoS One, 10, 2015, e0140311, 10.1371/journal.pone.0140311.
51. Ishiki, A., Okamura, N., Furukawa, K., Furumoto, S., Harada, R., Tomita, N., Hiraoka, K., Watanuki, S., Ishikawa, Y., Tago, T., Funaki, Y., Iwata, R., Tashiro, M., Yanai, K., Kudo, Y., Arai, H., Longitudinal assessment of tau pathology in patients with Alzheimer's disease using [18F]THK-5117 positron emission tomography. PLoS One, 10, 2015, e0140311, 10.1371/journal.pone.0140311.
52. Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M., Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., Donohue, M.C., Trojanowski, J.Q., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12 (2013), 207–216, 10.1016/S1474-4422(12)70291-0.
53. Jack, C.R., Hampel, H.J., Universities, S., Cu, M., Petersen, R.C., A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 0 (2016), 1–10.
54. Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., Marshall, G., Albers, M., Mauro, S., Pepin, L., Alverio, J., Judge, K., Philiossaint, M., Shoup, T., Yokell, D., Dickerson, B., Gomez-Isla, T., Hyman, B., Vasdev, N., Sperling, R., Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79 (2016), 110–119, 10.1002/ana.24546.
55. Jonasson, M., Wall, A., Chiotis, K., Saint-Aubert, L., Wilking, H., Sprycha, M., Borg, B., Thibblin, A., Eriksson, J., Sörensen, J., Antoni, G., Nordberg, A., Lubberink, M., Tracer kinetic analysis of (S)-18F-THK5117 as a PET tracer for assessing tau pathology. J. Nucl. Med. 57 (2016), 574–581, 10.2967/jnumed.115.158519.
56. Kantarci, K., Lowe, V.J., Boeve, B.F., Senjem, M.L., Tosakulwong, N., Lesnick, T.G., Spychalla, A.J., Gunter, J.L., Fields, J.A., Graff-Radford, J., Ferman, T.J., Jones, D.T., Murray, M.E., Knopman, D.S., Jack, C.R., Petersen, R.C., AV-1451 tau and β-amyloid PET imaging in dementia with lewy bodies. Ann. Neurol., 2016, 1–35, 10.1002/ana.24825.
57. Karran, E., Hardy, J., Antiamyloid therapy for Alzheimer's disease–are we on the right road?. N. Engl. J. Med 370 (2014), 377–378, 10.1056/NEJMe1313943.
58. Kepe, V., Bordelon, Y., Boxer, A., Huang, S.C., Liu, J., Thiede, F.C., Mazziotta, J.C., Mendez, M.F., Donoghue, N., Small, G.W., Barrio, J.R., PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J. Alzheimer's Dis. 36 (2013), 145–153, 10.3233/JAD-130032.
59. Kertesz, A., McMonagle, P., Blair, M., Davidson, W., Munoz, D.G., The evolution and pathology of frontotemporal dementia. Brain 128 (2005), 1996–2005, 10.1093/brain/awh598.
60. Kimura, Y., Ichise, M., Ito, H., Shimada, H., Ikoma, Y., Seki, C., Takano, H., Kitamura, S., Shinotoh, H., Kawamura, K., Zhang, M.-R., Sahara, N., Suhara, T., Higuchi, M., PET quantification of tau pathology in human brain with 11C-PBB3. J. Nucl. Med., 2015, 1359–1365, 10.2967/jnumed.115.160127.
61. Klunk, W.E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D.P., Bergstro, M., Savitcheva, I., Debnath, M.L., Barletta, J., Price, J.C., Sandell, J., Lopresti, B.J., Wall, A., Koivisto, P., Antoni, G., Mathis, C.A., Långstro, B., Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol., 2004, 306–319, 10.1002/ana.20009.
62. Kuzuhara, S., Ihara, Y., Toyokura, Y., Shimada, H., A semiquantitative study on Alzheimer neurofibrillary tangles demonstrated immunohistochemically with anti-tau antibodies, in the brains of non-demented and demented old people. No To Shinkei 41 (1989), 465–470.
63. Lammertsma, A., Hume, S.P., Simplified reference tissue model for PET receptor studies. Neuroimage 4 (1996), 153–158, 10.1006/nimg.1996.0066.
64. Lemoine, L., Saint-Aubert, L., Marutle, A., Antoni, G., Eriksson, J.P., Ghetti, B., Okamura, N., Nennesmo, I., Gillberg, P.-G., Nordberg, A., Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol. Commun., 3, 2015, 40, 10.1186/s40478-015-0220-4.
65. Logan, J., Fowler, J.S., Volkow, N.D., Wolf, A.P., Dewey, S.L., Schlyer, D.J., MacGregor, R.R., Hitzemann, R., Bendriem, B., Gatley, S.J., Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 10 (1990), 740–747, 10.1038/jcbfm.1990.127.
66. Logan, J., Fowler, J.S., Volkow, N.D., Wang, G.J., Ding, Y.S., Alexoff, D.L., Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 16 (1996), 834–840.
67. Lopera, F., Giraldo, M., Acosta, N., Munoz, C., Moreno, S., Tirado, V., Garcia Ospina, G.P., Langbaum, J., Ho, C., Suliman, S., Cho, W., Tariot, P., Reiman, E., Alzheimer's prevention initiative Colombia registry in the PSEN1 E280A mutation kindred. Alzheimer's Dement., 9, 2013, P321, 10.1016/j.jalz.2013.04.151.
68. Lowe, V.J., Curran, G., Fang, P., Liesinger, A.M., Josephs, K.A., Parisi, J.E., Kantarci, K., Boeve, B.F., Pandey, M.K., Bruinsma, T., Knopman, D.S., Jones, D.T., Petrucelli, L., Cook, C.N., Graff-Radford, N.R., Dickson, D.W., Petersen, R.C., Jack, C.R., Murray, M.E., An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol. Commun., 4, 2016, 58, 10.1186/s40478-016-0315-6.
69. Mak, E., Su, L., Williams, G., O'Brien, J., Neuroimaging characteristics of dementia with Lewy bodies. Alzheimers Res. Ther., 6, 2014, 18.
70. Mak, E., Su, L., Williams, G.B., Watson, R., Firbank, M., Blamire, A.M., O'Brien, J.T., Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. NeuroImage Clin. 7 (2015), 456–462, 10.1016/j.nicl.2015.01.017.
71. Mak, E., Su, L., Williams, G.B., Watson, R., Firbank, M., Blamire, A.M., O'Brien, J.T., Differential atrophy of hippocampal subfields: a comparative study of dementia with Lewy bodies and Alzheimer's disease. Am. J. Geriatr. Psychiatry 24 (2015), 136–143, 10.1016/j.jagp.2015.06.006.
72. Mak, E., Gabel, S., Su, L., Williams, G.B., Arnold, R., Passamonti, L., Rodríguez, P.V., Surendranathan, A., Bevan-jones, W.R., Rowe, J.B., O'Brien, J.T., Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies. Int. Psychogeriatr., 2017, 1–11, 10.1017/s1041610216002143.
73. Marquié, M., Normandin, M.D., Vanderburg, C.R., Costantino, I.M., Bien, E.A., Rycyna, L.G., Klunk, W.E., Mathis, C.A., Ikonomovic, M.D., Debnath, M.L., Vasdev, N., Dickerson, B.C., Gomperts, S.N., Growdon, J.H., Johnson, K.A., Frosch, M.P., Hyman, B.T., Gómez-Isla, T., Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann. Neurol. 78 (2015), 787–800, 10.1002/ana.24517.
74. Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.R., Trojanowski, J., Lee, V.Y., Ono, M., Masamoto, K., Takano, H., Sahara, N., Iwata, N., Okamura, N., Furumoto, S., Kudo, Y., Chang, Q., Saido, T., Takashima, A., Lewis, J., Jang, M.K., Aoki, I., Ito, H., Higuchi, M., Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108, 10.1016/j.neuron.2013.07.037.
75. Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.R., Trojanowski, J., Lee, V.Y., Ono, M., Masamoto, K., Takano, H., Sahara, N., Iwata, N., Okamura, N., Furumoto, S., Kudo, Y., Chang, Q., Saido, T., Takashima, A., Lewis, J., Jang, M.K., Aoki, I., Ito, H., Higuchi, M., Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108, 10.1016/j.neuron.2013.07.037.
76. McAleese, K.E., Firbank, M., Dey, M., Colloby, S.J., Walker, L., Johnson, M., Beverley, J.R., Taylor, J.P., Thomas, A.J., O'Brien, J.T., Attems, J., Cortical tau load is associated with white matter hyperintensities. Acta Neuropathol. Commun., 3, 2015, 60, 10.1186/s40478-015-0240-0.
77. Mckeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Arai, H., Ballard, C.G., Boeve, B., Burn, D.J., Costa, D., Del Ser, T., Dubois, B., Galasko, D., Gauthier, S., Goetz, C.G., Gomez-Tortosa, E., Halliday, G., Hansen, L.A., Hardy, J., Iwatsubo, T., Kalaria, R.N., Kaufer, D., Kenny, R.A., Korczyn, A., Kosaka, K., Lee, V.M., Lees, A., Litvan, I., Londos, E., Lopez, O.L., Minoshima, S., Mizuno, Y., Molina, J.A., Mukaetova-Ladinska, E.B., Pasquier, F., Perry, R.H., Schulz, J.B., Trojanowski, J.Q., Yamada, M., Brien, J.T.O., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K., Aarsland, D., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65 (2005), 1863–1872, 10.1212/01.wnl.0000187889.17253.b1.
78. Mosconi, L., Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies. Clin. Transl. Imaging 1 (2013), 997–1003, 10.1016/j.biotechadv.2011.08.021.Secreted.
79. Moussaud, S., Jones, D.R., Moussaud-Lamodière, E.L., Delenclos, M., Ross, O.A., McLean, P.J., Alpha-synuclein and tau: teammates in neurodegeneration?. Mol. Neurodegener., 9, 2014, 43, 10.1186/1750-1326-9-43.
80. Neary, D., Snowden, J.S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P.H., Albert, M., Boone, K., Miller, B.L., Cummings, J., Benson, D.F., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998), 1546–1554.
81. Nedelska, Z., Ferman, T.J., Boeve, B.F., Przybelski, S.A., Lesnick, T.G., Murray, M.E., Gunter, J.L., Senjem, M.L., Vemuri, P., Smith, G.E., Geda, Y.E., Graff-Radford, J., Knopman, D.S., Petersen, R.C., Parisi, J.E., Dickson, D.W., Jack, C.R., Kantarci, K., Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiol. Aging 36:1 (2015), 452–461, 10.1016/j.neurobiolaging.2014.07.005.
82. Normandin, M.D., Vanderburg, C.R., Ba, I.M.C., Bs, E.A.B., Bs, L.G.R., Klunk, W.E., Mathis, C.A., Ikonomovic, M.D., Ms, M.L.D., Vasdev, N., Dickerson, B.C., Gomperts, S.N., Growdon, J.H., Johnson, K.A., Frosch, M.P., Validating novel tau positron EmissionTomography tracer [F-18]-AV-1451 (T807)on postmortem brain tissue. Ann. Neurol. 78 (2015), 787–800, 10.1002/ana.24517.
83. O'Brien, J.T., Herholz, K., Amyloid imaging for dementia in clinical practice. BMC Med., 13, 2015, 163, 10.1186/s12916-015-0404-6.
84. Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Fujiwara, H., Nemoto, M., Maruyama, M., Arai, H., Yanai, K., Sawada, T., Kudo, Y., Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J. Neurosci. 25 (2005), 10857–10862, 10.1523/JNEUROSCI.1738-05.2005.
85. Okamura, N., Furumoto, S., Harada, R., Tago, T., Yoshikawa, T., Fodero-Tavoletti, M.T., Mulligan, R.S., Villemagne, V.L., Akatsu, H., Yamamoto, T., Arai, H., Iwata, R., Yanai, K., Kudo, Y., Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J. Nucl. Med. 54 (2013), 1420–1427, 10.2967/jnumed.112.117341.
86. Okamura, N., Furumoto, S., Fodero-Tavoletti, M.T., Mulligan, R.S., Harada, R., Yates, P., Pejoska, S., Kudo, Y., Masters, C.L., Yanai, K., Rowe, C.C., Villemagne, V.L., Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137 (2014), 1762–1771, 10.1093/brain/awu064.
87. Okamura, N., Harada, R., Furukawa, K., Furumoto, S., Tago, T., Yanai, K., Arai, H., Kudo, Y., Advances in the development of tau PET radiotracers and their clinical applications. Ageing Res. Rev. 30 (2015), 107–113, 10.1016/j.arr.2015.12.010.
88. Ossenkoppele, R., Schönhaut, D.R., Schö, M., Lockhart, S.N., Ayakta, N., Baker, S.L.,'neil, O., Janabi, J.P., Lazaris, M., Cantwell, A., Vogel, A., Santos, J., Miller, M., Bettcher, Z.A., Vossel, B.M., Kramer, K.A., Gorno-Tempini, J.H., Miller, M.L., Jagust, B.L., Rabinovici, W.J., Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain, 2016, 1–17, 10.1093/brain/aww027.
89. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain, 2017, aww340, 10.1093/brain/aww340.
90. Patel, N., Ramachandran, S., Azimov, R., Kagan, B.L., Lal, R., Ion channel formation by tau protein: implications for Alzheimer's disease and tauopathies. Biochemistry 54 (2015), 7320–7325, 10.1021/acs.biochem.5b00988.
91. Pini, L., Pievani, M., Bocchetta, M., Altomare, D., Bosco, P., Cavedo, E., Galluzzi, S., Marizzoni, M., Frisoni, G.B., Brain atrophy in Alzheimer's disease and aging. Ageing Res. Rev. 30 (2016), 1–24, 10.1016/j.arr.2016.01.002.
92. Rademakers, R., Cruts, M., Van Broeckhoven, C., The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum. Mutat. 24 (2004), 277–295, 10.1002/humu.20086.
93. Rizzu, P., Van Swieten, J.C., Joosse, M., Hasegawa, M., Stevens, M., Tibben, A., Niermeijer, M.F., Hillebrand, M., Ravid, R., Oostra, B.A., Goedert, M., van Duijn, C.M., Heutink, P., High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. Am. J. Hum. Genet. 64 (1999), 414–421, 10.1086/302256.
94. Rohrer, J.D., Rosen, H.J., Neuroimaging in frontotemporal dementia. Int. Rev. Psychiatry 25 (2013), 221–229, 10.3109/09540261.2013.778822.
95. Rowe, C.C., Ellis, K.A., Rimajova, M., Bourgeat, P., Pike, K.E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., Price, R., Raniga, P., Robins, P., Acosta, O., Lenzo, N., Szoeke, C., Salvado, O., Head, R., Martins, R., Masters, C.L., Ames, D., Villemagne, V.L., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging Imaging 31 (2010), 1275–1283, 10.1016/j.neurobiolaging.2010.04.007.
96. Saint-Aubert, L., Almkvist, O., Chiotis, K., Almeida, R., Wall, A., Nordberg, A., Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. Alzheimers. Res. Ther., 8, 2016, 38, 10.1186/s13195-016-0204-z.
97. Sander, K., Lashley, T., Gami, P., Gendron, T., Lythgoe, M.F., Rohrer, J.D., Schott, J.M., Revesz, T., Fox, N.C., Arstad, E., Characterization of tau positron emission tomography tracer [18F] AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimer's Dement., 2016, 1–9, 10.1016/j.jalz.2016.01.003.
98. Sarro, L., Senjem, M.L., Lundt, E.S., Przybelski, S.A., Lesnick, T.G., Graff-Radford, J., Boeve, B.F., Lowe, V.J., Ferman, T.J., Knopman, D.S., Comi, G., Filippi, M., Petersen, R.C., Jack, C.R., Kantarci, K., Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 10.1093/brain/ww193 aww193.
99. Sasamoto, A., Miyata, J., Kubota, M., Hirao, K., Kawada, R., Fujimoto, S., Tanaka, Y., Hazama, M., Sugihara, G., Sawamoto, N., Fukuyama, H., Takahashi, H., Murai, T., Global association between cortical thinning and white matter integrity reduction in schizophrenia. Schizophr. Bull. 40 (2014), 420–427, 10.1093/schbul/sbt030.
100. Schöll, M., Lockhart, S.N., Schönhaut, D.R., Schwimmer, H.D., Rabinovici, G.D., Correspondence, W.J.J., Schö Ll, M., O'neil, J.P., Janabi, M., Ossenkoppele, R., Baker, S.L., Vogel, J.W., Faria, J., Jagust, W.J., PET imaging of tau deposition in the aging human brain. Neuron, 2016, 971–982, 10.1016/j.neuron.2016.01.028.
101. Schafer, K.N., Kim, S., Matzavinos, A., Kuret, J., Selectivity requirements for diagnostic imaging of neurofibrillary lesions in Alzheimer's disease: a simulation study. Neuroimage 60 (2012), 1724–1733, 10.1016/j.neuroimage.2012.01.066.
102. 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain, 2016, 10.1093/brain/aww023 aww023.
103. Sepulcre, J., Schultz, A.P., Sabuncu, M., Gomez-Isla, T., Chhatwal, J., Becker, A., Sperling, R., Johnson, K.A., In vivo tau amyloid, and gray matter profiles in the aging brain. J. Neurosci. 36 (2016), 7364–7374, 10.1523/JNEUROSCI.0639-16.2016.
104. Shcherbinin, S., Schwarz, A.J., Joshi, A.D., Navitsky, M., Flitter, M., Shankle, W.R., Devous, M.D., Mintun, M.A., Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment and Alzheimers disease. J. Nucl. Med., 2016, 1451, 10.2967/jnumed.115.170027.
105. Siemers, E.R., Sundell, K.L., Carlson, C., Case, M., Sethuraman, G., Liu-Seifert, H., Dowsett, S.A., Pontecorvo, M.J., Dean, R.A., Demattos, R., Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimer's Dement. 12 (2015), 1–11, 10.1016/j.jalz.2015.06.1893.
106. Small, G.W., Kepe, V., Ercoli, L.M., Siddarth, P., Bookheimer, S.Y., Miller, K.J., Lavretsky, H., Burggren, A.C., Cole, G.M., Vinters, H.V., Thompson, P.M., Huang, S.-C., Satyamurthy, N., Phelps, M.E., Barrio, J.R., PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 355 (2006), 2652–2663, 10.1056/NEJMoa054625.
107. Smith, R., Puschmann, A., Schöll, M., Ohlsson, T., van Swieten, J., Honer, M., Englund, E., Hansson, O., 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain, 2016, 10.1093/brain/aww163 aww163.
108. Smith, R., Schain, M., Nilsson, C., Strandberg, O., Olsson, T., Hägerström, D., Jögi, J., Borroni, E., Schöll, M., Honer, M., Hansson, O., Increased basal ganglia binding of 18F-AV-1451 in patients with progressive supranuclear palsy. Mov. Disord. 0 (2016), 1–7, 10.1002/mds.26813.
109. Smith, R., Wibom, M., Olsson, T., Hägerström, D., Jögi, J., Rabinovici, G.D., Hansson, O., Posterior accumulation of tau and concordant hypometabolism in an early-onset Alzheimer's disease patient with presenilin-1 mutation. J. Alzheimer's Dis. 51 (2016), 339–343, 10.3233/JAD-151004.
110. Sokoloff, L., Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed. Proc. 40 (1981), 2311–2316.
111. Spillantini, M.G., Goedert, M., Tau pathology and neurodegeneration. Lancet Neurol. 12 (2013), 609–622, 10.1016/S1474-4422(13)70090-5.
112. Stancu, I.-C., Vasconcelos, B., Terwel, D., Dewachter, I., Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism. Mol. Neurodegener., 9, 2014, 51, 10.1186/1750-1326-9-51.
113. Steele, J., Richardson, J., Olszewski, J., Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10 (1964), 333–359.
114. Stefaniak, J., O'Brien, J., Imaging of neuroinflammation in dementia: a review. J. Neurol. Neurosurg. Psychiatry, 2015, 21–28, 10.1136/jnnp-2015-311336.
115. Surendranathan, A., Rowe, J.B., O'Brien, J.T., Neuroinflammation in Lewy body dementia. Parkinsonism Relat. Disord. 21 (2015), 1398–1406, 10.1016/j.parkreldis.2015.10.009.
116. Trojanowski, J.Q., Vandeerstichele, H., Korecka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W.Z., Weiner, M.W., Jack, C.R., Jagust, W., Toga, A.W., Lee, V.M.Y., Shaw, L.M., Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's Dement. 6 (2010), 230–238, 10.1016/j.jalz.2010.03.008.
117. Van Rossum, I.A., Visser, P.J., Knol, D.L., Van Der Flier, W.M., Teunissen, C.E., Barkhof, F., Blankenstein, M.A., Scheltens, P., Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in alzheimer's disease. J. Alzheimer's Dis. 29 (2012), 319–327, 10.3233/JAD-2011-111694.
118. Villemagne, V.L., Chételat, G., Neuroimaging biomarkers in Alzheimer's disease and other dementias. Ageing Res. Rev. 30 (2016), 1–13, 10.1016/j.arr.2016.01.004.
119. Villemagne, V.L., Furumoto, S., Fodero-Tavoletti, M.T., Mulligan, R.S., Hodges, J., Harada, R., Yates, P., Piguet, O., Pejoska, S., Doré, V., Yanai, K., Masters, C.L., Kudo, Y., Rowe, C.C., Okamura, N., In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 41 (2014), 816–826, 10.1007/s00259-013-2681-7.
120. Villemagne, V.L., Fodero-Tavoletti, M.T., Masters, C.L., Rowe, C.C., Tau imaging: early progress and future directions. Lancet Neurol. 14 (2015), 114–124, 10.1016/S1474-4422(14)70252-2.
121. 18F]-MK-6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J. Med. Chem. 59 (2016), 4778–4789, 10.1021/acs.jmedchem.6b00166.
122. Wang, Y., Mandelkow, E., Tau in physiology and pathology. Nat. Rev. Neurosci. 17 (2015), 22–35, 10.1038/nrn.2015.1.
123. Wang, L., Benzinger, T.L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., McConathy, J., Cairns, N.J., Fagan, A.M., Morris, J.C., Ances, B.M., Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between β-amyloid and tauopathy. JAMA Neurol 73 (2016), 1070–1077, 10.1001/jamaneurol.2016.2078.
124. Whitwell, J.L., Jack, C.R. Jr., Parisi, J.E., Knopman, D.S., Boeve, B.F., Petersen, R.C., Ferman, T.J., Dickson, D.W., Josephs, K.A., Rates of cerebral atrophy differ in different degenerative pathologies. Brain 130 (2007), 1148–1158, 10.1093/brain/awm021.
125. 18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov. Disord. 0 (2016), 1–10, 10.1002/mds.26834.
126. Williams, D.R., Holton, J.L., Strand, C., Pittman, A., Silva, R., Lees, De, Revesz, A.J., Pathological tau burden and distribution distinguishes progressive supranuclear Palsy-Parkinsonism from Richardson's syndrome. Brain, 2007, 1566–1576, 10.1093/brain/awm104.
127. Wischik, C., Staff, R., Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of tau-aggregation inhibitor therapy. J. Nutr. Heal. Aging 13 (2009), 367–369, 10.1007/s12603-009-0046-5.
128. Wong, D.F., Borroni, E., Kuwabara, H., George, N., Rosenberg, P., Lyketsos, C., Resnick, S.M., Thambisetty, M., Brasic, J., Gapasin, L., Willis, W., Knust, H., Guerard, M., Belli, S., Muri, D., Carey, T., Bedding, A., Wandel, C., Hansrod, T., Honer, M., Moghekar, A., Boess, F., Albert, M.S., Shaya, E., Oh, E., Ostrowitzki, S., Dannals, R.F., Comley, R.A., First in-human PET study of 3 novel tau radiopharmaceuticals: [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948. Alzheimer's Dement. 11 (2015), P850–P851, 10.1016/j.jalz.2015.08.013.
129. Wooten, D., Guehl, N.J., Verwer, E.E., Shoup, T.M., Yokell, D.L., Zubcevik, N., Vasdev, N., Zafonte, R.D., Johnson, K.A., El Fakhri, G., Normandin, M.D., Pharmacokinetic evaluation of the tau PET radiotracer [18F]T807 ([18F]AV-1451) in human subjects. J. Nucl. Med. 807 (2016), 1–27, 10.2967/jnumed.115.170910.
130. Xia, C.F., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L.F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V.P., Mu, F., Sinha, A., Su, H., Szardenings, A.K., Walsh, J.C., Wang, E., Yu, C., Zhang, W., Zhao, T., Kolb, H.C., [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 9 (2013), 666–676, 10.1016/j.jalz.2012.11.008.
131. Xia, C.F., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L.F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V.P., Mu, F., Sinha, A., Su, H., Szardenings, A.K., Walsh, J.C., Wang, E., Yu, C., Zhang, W., Zhao, T., Kolb, H.C., [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 9 (2013), 666–676, 10.1016/j.jalz.2012.11.008.
132. Yanamandra, K., Jiang, H., Mahan, T.E., Maloney, S.E., Wozniak, D.F., Diamond, M.I., Holtzman, D.M., David Holtzman, C.M., Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2 (2015), 278–288, 10.1002/acn3.176.
133. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q., Lee, V.M.Y., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53 (2007), 337–351, 10.1016/j.neuron.2007.01.010.
134. van Berckel, B.N.M., Ossenkoppele, R., Tolboom, N., Yaqub, M., Foster-Dingley, J.C., Windhorst, A.D., Scheltens, P., Lammertsma, A.A., Boellaard, R., Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J. Nucl. Med. 54 (2013), 1570–1576, 10.2967/jnumed.112.113654.